JP2018535701A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535701A5
JP2018535701A5 JP2018546725A JP2018546725A JP2018535701A5 JP 2018535701 A5 JP2018535701 A5 JP 2018535701A5 JP 2018546725 A JP2018546725 A JP 2018546725A JP 2018546725 A JP2018546725 A JP 2018546725A JP 2018535701 A5 JP2018535701 A5 JP 2018535701A5
Authority
JP
Japan
Prior art keywords
cell
item
antigen
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018546725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535701A (ja
JP6976960B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2016/051141 external-priority patent/WO2017088012A1/en
Publication of JP2018535701A publication Critical patent/JP2018535701A/ja
Publication of JP2018535701A5 publication Critical patent/JP2018535701A5/ja
Priority to JP2021183110A priority Critical patent/JP2022027762A/ja
Application granted granted Critical
Publication of JP6976960B2 publication Critical patent/JP6976960B2/ja
Priority to JP2024010098A priority patent/JP2024028648A/ja
Priority to JP2025265629A priority patent/JP7864244B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018546725A 2015-11-27 2016-11-23 遺伝子改変された細胞およびその使用 Active JP6976960B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021183110A JP2022027762A (ja) 2015-11-27 2021-11-10 遺伝子改変された細胞およびその使用
JP2024010098A JP2024028648A (ja) 2015-11-27 2024-01-26 遺伝子改変された細胞およびその使用
JP2025265629A JP7864244B2 (ja) 2015-11-27 2025-12-18 遺伝子改変された細胞およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2015904933A AU2015904933A0 (en) 2015-11-27 Genetically modified cells and uses thereof
AU2015904933 2015-11-27
AU2016901328 2016-04-11
AU2016901328A AU2016901328A0 (en) 2016-04-11 Genetically modified cells and uses thereof - III
PCT/AU2016/051141 WO2017088012A1 (en) 2015-11-27 2016-11-23 Genetically modified cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021183110A Division JP2022027762A (ja) 2015-11-27 2021-11-10 遺伝子改変された細胞およびその使用

Publications (3)

Publication Number Publication Date
JP2018535701A JP2018535701A (ja) 2018-12-06
JP2018535701A5 true JP2018535701A5 (enExample) 2019-12-26
JP6976960B2 JP6976960B2 (ja) 2021-12-08

Family

ID=58762790

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018546725A Active JP6976960B2 (ja) 2015-11-27 2016-11-23 遺伝子改変された細胞およびその使用
JP2021183110A Pending JP2022027762A (ja) 2015-11-27 2021-11-10 遺伝子改変された細胞およびその使用
JP2024010098A Pending JP2024028648A (ja) 2015-11-27 2024-01-26 遺伝子改変された細胞およびその使用
JP2025265629A Active JP7864244B2 (ja) 2015-11-27 2025-12-18 遺伝子改変された細胞およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021183110A Pending JP2022027762A (ja) 2015-11-27 2021-11-10 遺伝子改変された細胞およびその使用
JP2024010098A Pending JP2024028648A (ja) 2015-11-27 2024-01-26 遺伝子改変された細胞およびその使用
JP2025265629A Active JP7864244B2 (ja) 2015-11-27 2025-12-18 遺伝子改変された細胞およびその使用

Country Status (11)

Country Link
US (3) US11400145B2 (enExample)
EP (3) EP3708587B1 (enExample)
JP (4) JP6976960B2 (enExample)
CN (2) CN116121281B (enExample)
AU (2) AU2016361451B2 (enExample)
CA (1) CA3004120A1 (enExample)
ES (2) ES2988976T3 (enExample)
IL (2) IL296410A (enExample)
MY (1) MY189819A (enExample)
SG (2) SG10201912825XA (enExample)
WO (1) WO2017088012A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201707182WA (en) 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
JP6976960B2 (ja) * 2015-11-27 2021-12-08 カーサリクス プロプライエタリー リミテッド 遺伝子改変された細胞およびその使用
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
JP7215994B2 (ja) 2016-09-06 2023-01-31 ザ チルドレンズ メディカル センター コーポレーション 人工多能性幹細胞由来の免疫細胞
US11725210B2 (en) 2017-03-17 2023-08-15 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
EP3606550A2 (en) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
CN110891967B (zh) * 2017-04-18 2025-03-14 富士胶片细胞动力公司 抗原特异性免疫效应细胞
KR102742741B1 (ko) 2017-10-18 2024-12-16 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
CN109971716B (zh) * 2017-12-28 2023-08-01 上海细胞治疗研究院 自分泌cd47抗体的egfr特异性car-t细胞及其用途
SG11202007622SA (en) 2018-02-11 2020-09-29 Memorial Sloan Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
AU2019225393A1 (en) * 2018-02-23 2020-08-20 Cartherics Pty. Ltd. T cell disease treatment targeting TAG-72
GB201804701D0 (en) * 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
GB201807945D0 (en) * 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Vector production
US20200040056A1 (en) * 2018-05-31 2020-02-06 Washington University Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
EP3830133A1 (en) 2018-08-01 2021-06-09 City of Hope Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors
AU2020291457B2 (en) * 2019-06-12 2024-11-14 The Regents Of The University Of California Engineered off-the-shelf immune cells and methods of use thereof
BR112022009181A2 (pt) 2019-11-25 2022-07-26 Univ Kyoto Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula t
CN117843812A (zh) * 2020-05-22 2024-04-09 重庆精准生物技术有限公司 逆转肿瘤微环境的融合蛋白及其应用
EP4161536A4 (en) 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
WO2022061837A1 (en) * 2020-09-27 2022-03-31 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Fibronectin extra domain b (edb) -specific car-t for cancer
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CA3214473A1 (en) * 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
AU2022252997A1 (en) * 2021-04-07 2023-09-28 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
WO2023110824A1 (en) * 2021-12-15 2023-06-22 Novo Nordisk A/S Novel integrin associated protein (iap)
CN114573710A (zh) * 2022-02-16 2022-06-03 南方医科大学珠江医院 一种靶向抗原同时外泌cd47抗体的免疫细胞及其应用
WO2024036214A2 (en) * 2022-08-10 2024-02-15 Jasper Therapeutics, Inc. Modified stem cell compositions and methods for use
WO2026096885A1 (en) * 2024-11-01 2026-05-07 The Medical College Of Wisconsin, Inc. Compositions that target cd47 and cd138 and methods of making and using the same

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
EP0937095A4 (en) * 1996-10-25 1999-12-22 Cell Genesys Inc TARGETED CYTOLYSIS OF CANCER CELLS
US6908763B1 (en) 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
DE60036470T2 (de) 1999-06-29 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto Untereinheiten von myeloid-progenitorzellen von säugern
US6761883B2 (en) 1999-06-29 2004-07-13 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
DE10130800B4 (de) 2001-06-22 2005-06-23 Epigenomics Ag Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003273542A1 (en) 2002-05-31 2003-12-19 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying and isolating stem cells and cancer stem cells
US7592174B2 (en) 2002-05-31 2009-09-22 The Board Of Trustees Of The Leland Stanford Junior University Isolation of mesenchymal stem cells
ATE539146T1 (de) 2002-09-13 2012-01-15 Univ Leland Stanford Junior Säugetier-megakaryozytenstammzelle
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2005021594A2 (en) * 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
JPWO2005035586A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2546465A1 (en) 2003-12-05 2005-06-23 The Board Of Trustees Of The Leland Stanford Junior University Identification, isolation and elimination of cancer stem cells
US7749754B2 (en) 2004-06-09 2010-07-06 The Board Of Trustees Of The Leland Stanford Junior University Isolation and characterization of muscle regenerating cells
US7641897B2 (en) 2004-11-23 2010-01-05 The Board Of Trustees Of The Leland Stanford Junior University Feeder layer and serum independent embryonic stem cells
US20060188508A1 (en) 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
DK1877102T3 (da) * 2005-04-28 2014-07-21 Danisco Us Inc Tab-molekyler
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US8236313B2 (en) 2006-10-06 2012-08-07 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
WO2008073316A2 (en) 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of acute myeloid leukemia stem cells
US7781179B2 (en) 2006-12-07 2010-08-24 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of transitional cell carcinoma stem cells
US8765390B2 (en) 2006-12-08 2014-07-01 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of squamous carcinoma stem cells
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
JP5779090B2 (ja) 2008-04-09 2015-09-16 マックスサイト インコーポレーティッド 新規に単離された細胞の治療組成物の操作および送達
US8320687B2 (en) 2009-02-05 2012-11-27 The Board Of Trustees Of The Leland Stanford Junior University Universal lossy compression methods
CN105925535A (zh) * 2009-06-05 2016-09-07 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
CA2766409C (en) * 2009-07-03 2023-04-25 Avipep Pty Ltd Immuno-conjugates and methods for producing them
SI2477648T1 (sl) 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
WO2011041453A1 (en) 2009-09-29 2011-04-07 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
WO2011094538A1 (en) 2010-01-29 2011-08-04 The Board Of Trustees Of The Leland Stanford Junior University Depletion of teratoma-forming pluripotent stem cells
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
EP3115373B1 (en) 2010-09-08 2019-08-28 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
ES2785081T3 (es) * 2011-04-01 2020-10-05 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
PL4019041T3 (pl) 2012-07-13 2023-05-08 The Trustees Of The University Of Pennsylvania Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR
KR20150029714A (ko) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
US9045734B2 (en) 2012-07-31 2015-06-02 The Board Of Trustees Of The Leland Stanford Junior University Isolation and characterization of progenitor cells from mesothelium
IL282953B2 (en) * 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
EP3789487A1 (en) * 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
US20160250258A1 (en) * 2013-10-31 2016-09-01 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3105333B1 (en) * 2014-02-10 2020-04-08 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
WO2016154628A1 (en) 2015-03-26 2016-09-29 Xiuli Wang Bi-specific targeted chimeric antigen receptor t cells
US12642852B1 (en) * 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
CN105331586B (zh) 2015-11-20 2020-09-15 上海细胞治疗研究院 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途
JP6976960B2 (ja) 2015-11-27 2021-12-08 カーサリクス プロプライエタリー リミテッド 遺伝子改変された細胞およびその使用

Similar Documents

Publication Publication Date Title
JP2020533958A5 (enExample)
JP2021500881A5 (enExample)
JP2017524367A5 (enExample)
JP2022002546A (ja) 細胞
JP2020517295A5 (enExample)
CA3158025C (en) Anti-bcma chimeric antigen receptors
JP2021137024A5 (enExample)
JP2024502632A5 (enExample)
JP2022534680A5 (enExample)
FI3703750T3 (fi) B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja
JP2016520074A5 (enExample)
JP2024028648A5 (enExample)
JP2023552998A (ja) 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
KR20230095083A (ko) Cd7 표적의 키메라 항원 수용체 및 이의 용도
JP2018532407A5 (enExample)
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
WO2012079000A4 (en) Use of chimeric antigen receptor-modified t cells to treat cancer
JP2024527557A5 (enExample)
JP2018527014A5 (enExample)
US11773384B2 (en) Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells
EP4273175A1 (en) Novel chimeric antigen receptor and use thereof
US20220133792A1 (en) Signaling platforms for chimeric antigen receptor t cells
JP2024534847A5 (enExample)
JP2023519346A5 (enExample)
IL304857A (en) Preparations and methods for treating HER2 POSITIVE cancer